BioCatalystWatch
ERNAWorkspace / ERNA / OverviewCompany library
Ernexa Therapeutics Inc. logo

Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc. (ERNA)

Website

Price
Market cap
Next catalystFirst-patient dosing / Phase 1 initiation in Q1 2027, subject to IND clearanceERNA-101 — planned first-in-human Phase 1 study · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

ERNA-101

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

ERNA-101

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Other pipelines

History / paused

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ERNA PR & News

PR & News

ERNA SEC archive